Anna Przybyłowicz-Chalecka

Statistics

Publications

Citations

282

H-Index

Active since

2016

Affiliations

Poznan University of Medical Sciences(Current)

Wroclaw Medical University

Instytut Hematologii i Transfuzjologi

University of Chicago

The Maria Sklodowska-Curie National Research Institute of Oncology

Anna Przybyłowicz-Chalecka is an author at Poznan University of Medical Sciences specializing in oncology, multiple myeloma treatment, and refractory multiple myeloma.

ORCID

Publications per year

2016–2024

Publications

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells

Ravyn M. Thompson, Dominik Dytfeld, Leticia Reyes et al. · Oncotarget · 2017 · 136 citations · Full text

Medicine, Oncology, Pharmacology +13

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy

Dominik Dytfeld, Magdalena Łuczak, Tomasz Wróbel et al. · Oncotarget · 2016 · 68 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Tadeusz Kubicki, Dominik Dytfeld, David R. Barnidge et al. · Blood · 2024 · 31 citations · Full text

Life Sciences, Biochemistry, Hematology +17

The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia

Magdalena Matuszak, Krzysztof Lewandowski, Anna Czyż et al. · Leukemia Research · 2016 · 18 citations

Life Sciences, Immunology, Oncology +7

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy

Magdalena Łuczak, Tadeusz Kubicki, Zuzanna Rzetelska et al. · Polskie Archiwum Medycyny Wewnętrznej · 2017 · 18 citations

Medicine, Oncology, Pharmacology +17

1–5 of 6